Colorectal Cancer Panel

What is Colorectal cancer panel test?

Colorectal cancer panel test is a molecular diagnostic panel performed on tumor tissue blocks (formalin-fixed paraffin-embedded, or FFPE samples) from patients with colorectal cancer. It uses advanced technology to detect mutations in three important genes: KRAS, NRAS and BRAF. Mutations in these genes can drive cancer growth and affect how a patient responds to certain targeted cancer therapies — especially anti-EGFR treatments.

Why consider Colorectal cancer panel test?

This test helps to:

• Identify patients who are eligible or ineligible for anti-EGFR therapy (like cetuximab or panitumumab).
• Detect actionable mutations to guide personalized treatment decisions.
• Stratify prognosis based on mutation status (e.g., BRAF V600E is linked to poor prognosis).
• Support selection of targeted therapies or enrolment in clinical trials.

Understanding these mutations improves treatment outcomes and avoids unnecessary therapies.

Who should get tested for Colorectal cancer panel test?

This test is recommended for:

• Patients diagnosed with colorectal adenocarcinoma, especially advanced or metastatic
• Individuals being considered for anti-EGFR monoclonal antibody therapy
• Patients with treatment-resistant colorectal cancer
• Oncologists planning precision oncology or targeted therapy approaches

More Information

OTHER NAMES: CRC Mutation Panel (KRAS/NRAS/BRAF), RAS and BRAF Mutation Testing, Colorectal Tumor Molecular Testing, Colorectal Cancer NGS Panel – Targeted Genes, FFPE Tumor Tissue Mutation Panel – Colorectal

Colorectal cancer is a type of cancer that starts in the colon or rectum, parts of the large intestine. It usually begins as benign growths called polyps which can become cancerous over time. CRC is one of the most common cancers worldwide. Early detection improves survival significantly. Diagnosis involve Colonoscopy, Fecal occult blood test (FOBT) or fecal immunochemical test (FIT), CT scans, MRI for staging and Molecular tests (e.g., COLORECTAL CANCER PROFILER NEXT) to detect mutations for personalized therapy.